A carregar...
The growing landscape of FLT3 inhibition in AML
Midostaurin and gilteritinib are FLT3 inhibitors that have been recently approved for use in FLT3-mutant acute myeloid leukemia (AML). These approved drugs represent a new standard of care for patients with FLT3 mutations in both the first-line and salvage settings. The success of midostaurin used i...
Na minha lista:
| Publicado no: | Hematology Am Soc Hematol Educ Program |
|---|---|
| Autor principal: | |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
American Society of Hematology
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6913436/ https://ncbi.nlm.nih.gov/pubmed/31808872 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/hematology.2019000058 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|